{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:48:22Z","timestamp":1782499702936,"version":"3.54.5"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The clinical significance of endocrine therapy (ET) in patients with estrogen receptor\u2013low (ER-low, 1%-10%) breast cancer remains uncertain. Increasing evidence suggests that these tumors differ biologically from typical hormone receptor\u2013positive cancers, raising questions about the true benefit of ET in this subgroup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis was conducted in accordance with the PRISMA 2020 guidelines. PubMed, Embase, the Cochrane Library, and Web of Science were searched from inception to July 1, 2025. Hazard ratios (HRs) with corresponding 95% CIs for time-to-event outcomes were extracted directly or estimated from Kaplan\u2013Meier curves when not explicitly reported. Pooled analyses were performed using random-effects models to account for between-study heterogeneity. The protocol was registered in PROSPERO (CRD420251055521).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 6 retrospective observational studies involving 8765 patients with estrogen receptor\u2013low breast cancer were included. Endocrine therapy was associated with improved overall survival (OS) (HR 0.81, 95% CI 0.69-0.95; P\u2009=\u2009.01; I2 = 0%) and disease-free survival (DFS) (HR 0.64, 95% CI 0.45-0.90; P\u2009=\u2009.01; I2 = 0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Endocrine therapy was associated with improved OS and DFS in patients with estrogen receptor\u2013low breast cancer. These findings suggest that estrogen receptor\u2013low breast cancer should not be uniformly considered endocrine-insensitive and that routine omission of endocrine therapy should be approached cautiously. Given that the available evidence is derived from retrospective observational studies, further prospective studies are needed to identify patients most likely to benefit from endocrine therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag230","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:34:38Z","timestamp":1781004878000},"source":"Crossref","is-referenced-by-count":0,"title":["Association between endocrine therapy and survival outcomes in estrogen receptor\u2013low breast cancer: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"31","author":[{"given":"Fan","family":"Xia","sequence":"first","affiliation":[{"name":"Department of Oncology, West China School of Medicine, Sichuan University , Chengdu, 610000,","place":["China"]},{"name":"Department of Oncology, Sichuan University Affiliated Chengdu Second People\u2019s Hospital , Chengdu, 610000,","place":["China"]},{"name":"Department of Oncology, Chengdu Second People\u2019s Hospital , Chengdu, 610000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoBo","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, West China School of Medicine, Sichuan University , Chengdu, 610000,","place":["China"]},{"name":"Department of Respiratory and Critical Care Medicine, Sichuan University Affiliated Chengdu Second People\u2019s Hospital , Chengdu, 610000,","place":["China"]},{"name":"Department of Respiratory and Critical Care Medicine, Chengdu Second People\u2019s Hospital , Chengdu, 610000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, West China School of Public Health and West China Fourth Hospital, Sichuan University , Chengdu, 610000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiaoDong","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Oncology, West China School of Medicine, Sichuan University , Chengdu, 610000,","place":["China"]},{"name":"Department of Oncology, Sichuan University Affiliated Chengdu Second People\u2019s Hospital , Chengdu, 610000,","place":["China"]},{"name":"Department of Oncology, Chengdu Second People\u2019s Hospital , Chengdu, 610000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6253-7757","authenticated-orcid":false,"given":"Mei","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, West China School of Medicine, Sichuan University , Chengdu, 610000,","place":["China"]},{"name":"Department of Respiratory and Critical Care Medicine, Sichuan University Affiliated Chengdu Second People\u2019s Hospital , Chengdu, 610000,","place":["China"]},{"name":"Department of Respiratory and Critical Care Medicine, Chengdu Second People\u2019s Hospital , Chengdu, 610000,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2026062614021067600_oyag230-B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026062614021067600_oyag230-B2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3322\/caac.21777","article-title":"Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer","volume":"73","author":"Huppert","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026062614021067600_oyag230-B3","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1200\/JCO.24.01131","article-title":"Explaining the relationships between age, endocrine therapy persistence, and risk of recurrence in hormone receptor-positive early breast cancer: a nationwide cohort study","volume":"43","author":"Dumas","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062614021067600_oyag230-B4","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1078-0432.CCR-20-4635","article-title":"Prognostic value of ER and PgR expression and the impact of multi-clonal expression for recurrence in ductal carcinoma in situ: results from the UK\/ANZ DCIS trial","volume":"27","author":"Thorat","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026062614021067600_oyag230-B5","doi-asserted-by":"publisher","first-page":"113473","DOI":"10.1016\/j.ejca.2023.113473","article-title":"Quantitative expression of oestrogen receptor in breast cancer: clinical and molecular significance","volume":"197","author":"Makhlouf","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026062614021067600_oyag230-B6","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026062614021067600_oyag230-B7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41523-021-00308-7","article-title":"Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant\/adjuvant chemotherapy","volume":"7","author":"Dieci","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"2026062614021067600_oyag230-B8","doi-asserted-by":"publisher","first-page":"100886","DOI":"10.1016\/j.lanepe.2024.100886","article-title":"Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study","volume":"40","author":"Acs","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026062614021067600_oyag230-B9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejca.2021.02.020","article-title":"Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors: an analysis of 2765 patients from neoadjuvant clinical trials","volume":"148","author":"Villegas","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026062614021067600_oyag230-B10","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1158\/1078-0432.CCR-24-3435","article-title":"Global transcriptional complexity of estrogen receptor-low positive breast cancers in the prospective Swedish population-based SCAN-B cohort","volume":"31","author":"Kimbung","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026062614021067600_oyag230-B11","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1002\/cncr.34155","article-title":"De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: propensity-matched analysis from a prospectively maintained cohort","volume":"128","author":"Cai","year":"2022","journal-title":"Cancer"},{"key":"2026062614021067600_oyag230-B12","doi-asserted-by":"publisher","first-page":"e2100201","DOI":"10.1200\/PO.21.00201","article-title":"Validity of 1% hormonal receptor positivity cutoff by the ASCO\/College of American Pathologists guidelines at the Georgia Cancer Center","volume":"6","author":"Kreidieh","year":"2022","journal-title":"JCO Precis Oncol."},{"key":"2026062614021067600_oyag230-B13","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s12282-025-01730-6","article-title":"Treatment and prognosis of patients with hormone receptor-low positive (1%-10%) breast cancer: a retrospective propensity score-matched analysis","volume":"32","author":"Luo","year":"2025","journal-title":"Breast Cancer"},{"key":"2026062614021067600_oyag230-B14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.breast.2022.09.008","article-title":"Adjuvant endocrine therapy in patients with estrogen receptor-low positive breast cancer: a prospective cohort study","volume":"66","author":"Xie","year":"2022","journal-title":"Breast"},{"key":"2026062614021067600_oyag230-B15","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.3390\/cancers13195007","article-title":"Level of combined estrogen and progesterone receptor expression determines the eligibility for adjuvant endocrine therapy in breast cancer patients","volume":"13","author":"Ahn","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026062614021067600_oyag230-B16","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.1038\/s41598-025-90134-9","article-title":"Reassessing estrogen receptor expression thresholds for breast cancer prognosis in HER2-negative patients using shape restricted modeling","volume":"15","author":"Dong","year":"2025","journal-title":"Sci Rep"},{"key":"2026062614021067600_oyag230-B17","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41416-020-1009-1","article-title":"The significance of highlighting the oestrogen receptor low category in breast cancer","volume":"123","author":"Poon","year":"2020","journal-title":"Br J Cancer"},{"key":"2026062614021067600_oyag230-B18","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.3747\/co.24.3238","article-title":"Prognostic and predictive value of low estrogen receptor expression in breast cancer","volume":"24","author":"Bouchard-Fortier","year":"2017","journal-title":"Curr Oncol"},{"key":"2026062614021067600_oyag230-B19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.breast.2022.03.002","article-title":"Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer","volume":"63","author":"Luo","year":"2022","journal-title":"Breast"},{"key":"2026062614021067600_oyag230-B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clbc.2017.06.005","article-title":"Borderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysis","volume":"18","author":"Chen","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"2026062614021067600_oyag230-B21","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/annonc\/mdu053","article-title":"Which threshold for ER positivity? A retrospective study based on 9639 patients","volume":"25","author":"Yi","year":"2014","journal-title":"Ann Oncol"},{"key":"2026062614021067600_oyag230-B22","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1093\/annonc\/mdx397","article-title":"Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer","volume":"28","author":"Fujii","year":"2017","journal-title":"Ann Oncol"},{"key":"2026062614021067600_oyag230-B23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10549-021-06148-0","article-title":"Characterization of estrogen receptor-low-positive breast cancer","volume":"188","author":"Fei","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2026062614021067600_oyag230-B24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026062614021067600_oyag230-B25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"2026062614021067600_oyag230-B26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"2026062614021067600_oyag230-B27","doi-asserted-by":"publisher","DOI":"10.22514\/ejgo.2023.022","article-title":"Characteristics and prognosis of young breast cancer patients with low expression of estrogen receptor","author":"Wang","year":"2023","journal-title":"Eur J Gynaecol Oncol"},{"key":"2026062614021067600_oyag230-B28","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO-24-02263","article-title":"Endocrine therapy omission in estrogen receptor-low (1%-10%) early-stage breast cancer","volume":"43","author":"Choong","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026062614021067600_oyag230-B29","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1245\/s10434-023-14835-z","article-title":"Defining the biology of estrogen receptor-low-positive breast cancer","volume":"31","author":"Higgins","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026062614021067600_oyag230-B30","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"2026062614021067600_oyag230-B31","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/annonc\/mdz298","article-title":"Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis","volume":"30","author":"Ferreira","year":"2019","journal-title":"Ann Oncol"},{"key":"2026062614021067600_oyag230-B32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S0140-6736(25)01013-X","article-title":"Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy","volume":"406","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2025","journal-title":"Lancet"},{"key":"2026062614021067600_oyag230-B33","doi-asserted-by":"publisher","first-page":"100289","DOI":"10.1016\/j.esmoop.2021.100289","article-title":"The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis","volume":"6","author":"Paakkola","year":"2021","journal-title":"ESMO Open"},{"key":"2026062614021067600_oyag230-B34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41523-022-00448-4","article-title":"Impact of low versus negative estrogen\/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer","volume":"8","author":"Yoder","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"2026062614021067600_oyag230-B35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41523-023-00543-0","article-title":"Immune landscape of breast tumors with low and intermediate estrogen receptor expression","volume":"9","author":"Voorwerk","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"2026062614021067600_oyag230-B36","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1093\/jnci\/djae178","article-title":"Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer","volume":"116","author":"Massa","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2026062614021067600_oyag230-B37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12282-024-01657-4","article-title":"Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study","volume":"32","author":"Aoyama","year":"2025","journal-title":"Breast Cancer"},{"key":"2026062614021067600_oyag230-B38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s13058-025-02179-3","article-title":"Pathological response to pembrolizumab-based neoadjuvant therapy in ER-low vs ER-zero breast cancer: a Swedish population-based cohort study","volume":"27","author":"Steen","year":"2025","journal-title":"Breast Cancer Res"},{"key":"2026062614021067600_oyag230-B39","doi-asserted-by":"publisher","first-page":"105907","DOI":"10.1016\/j.esmoop.2025.105907","article-title":"PROMENADE: pembrolizumab for early ER-low\/HER2-negative breast cancer, real-world French cohort","volume":"10","author":"Cherifi","year":"2025","journal-title":"ESMO Open"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag230\/68508314\/oyag230.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag230\/68508314\/oyag230.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/7\/oyag230\/68508314\/oyag230.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:02:23Z","timestamp":1782496943000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag230\/8705539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag230","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,6]]},"article-number":"oyag230"}}